Elodie Gautier-Veyret

16PUBLICATIONS
33CO-AUTHORS
Molecular targetsGene and molecular therapyPredictive and prognostic markersPharmacogenomicsMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 22, 2026
Can pharmacokinetic/pharmacodynamic targets be achieved with voriconazole in the treatment of urinary tract infections caused by Candida spp. with reduced susceptibility to fluconazole?

|Nov 25, 2024
French-Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten.

Louis Lebreton, Jean-Christophe Boyer, Claire Lafay-Chebassier

|Nov 25, 2023
Early Exposure of Kidney Transplant Recipients with Chronic Antibody-Mediated Rejection to Tocilizumab-A Preliminary Study.

Capucine Arrivé, Marvin Jacquet, Elodie Gautier-Veyret

|Mar 15, 2023
Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: What are the explanatory factors?

Capucine Arrivé, Xavier Fonrose, Fabienne Thomas

|Oct 14, 2022
Variability of Isavuconazole Trough Concentrations during Longitudinal Therapeutic Drug Monitoring.

Léa Bolcato, Anne Thiebaut-Bertrand, Françoise Stanke-Labesque

|Sep 15, 2022
Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency.

Maud Maillard, Manon Launay, Bernard Royer

Pageof 3

Frequent Collaborators

3 joint publications

Françoise Stanke-Labesque

2 joint publications

Fabienne Thomas

2 joint publications

Lionel Rostaing

2 joint publications

Johan Noble